EGX closes on green note on July 6th    Venezuela vows to uphold sovereignty on 214th independence anniversary    Egypt's FM probes Gaza truce, Iran-Israel tensions with intl. figures    ADIB Egypt publishes second sustainability report for 2024    Over 215,000 projects funded under Mashrouak, exceeding EGP 33bn in May: Minister    Gaza ceasefire hopes rise amid intensifying Israeli strikes, mounting death toll    Egypt, Norway hold informal talks ahead of global plastic treaty negotiations    Greco-Roman tombs with hieroglyphic inscriptions discovered in Aswan    UN conference cites Egypt's 'NWFE' programme as model for development finance    Al-Sisi calls for unified efforts to hold elections in Libya, urges withdrawal of foreign forces    EGP edges down in Sunday morning currency trading    Egypt, Russia's Rosatom review grid readiness for El-Dabaa nuclear plant    Global tour for Korean 'K-Comics' launches in Cairo with 'Hellbound' exhibition    Egypt launches public-private partnership to curb c-sections, improve maternal, child health    Philip Morris Misr announces new price list effective 1 July    Egypt teams up with private sector to boost university rankings    Egypt reveals heritage e-training portal    Three ancient rock-cut tombs discovered in Aswan    Egypt condemns deadly terrorist attack in Niger    Egypt's FM, China's Wang discuss Iran-Israel escalation    Egypt's EHA, Schneider Electric sign MoU on sustainable infrastructure    Sisi launches new support initiative for families of war, terrorism victims    Grand Egyptian Museum opening delayed to Q4    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Egypt's EDA joins high-level Africa-Europe medicines regulatory talks    Egypt's Irrigation Minister urges scientific cooperation to tackle water scarcity    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    Egypt's Democratic Generation Party Evaluates 84 Candidates Ahead of Parliamentary Vote    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Cabinet approves establishment of national medical tourism council to boost healthcare sector    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Egypt's FM inspects Julius Nyerere Dam project in Tanzania    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Why isn't there a treatment or vaccine for Ebola?
Ebola is the new scare worldwide, and here are some of the answers to questions relating to the treatment
Published in Ahram Online on 03 - 08 - 2014

In the four decades since the Ebola virus was first identified in Africa, treatment hasn't changed much. There are no licensed drugs or vaccines for the deadly disease.
Some are being developed, but none have been rigorously tested in humans. One experimental treatment, though, was tried this week in an American aid worker sick with Ebola, according to the U.S-based group that she works for in Liberia.
Without a specific treatment, doctors and nurses focus on easing the disease's symptoms - fever, headache, vomiting and diarrhea - and on keeping patients hydrated and comfortable.
The outbreak in three West African countries - Liberia, Guinea and Sierra Leone - has sickened more than 1,300 people and more than 700 have died since March.
WHY ISN'T THERE A TREATMENT BY NOW?
For one thing, the Ebola virus is hard to work with. The virus doesn't grow well in petri dishes and experiments can only be done in the relatively few labs with the highest security measures. And while Ebola is lethal, it's rare. Outbreaks are unpredictable, giving doctors few chances to test new treatments. While the current epidemic is the largest recorded, the number of people sickened by Ebola is small compared to the number killed by other diseases like malaria or dengue. Much of the funding for Ebola research is from governments that worry about the virus being used in a bioterror attack. "It's not economically viable for any company to do this kind of research because they have stockholders to think about," said Ben Neuman, a virologist at the University of Reading in Britain.
WHAT'S IN THE PIPELINE?
There are about a half dozen Ebola drugs and vaccines in development, several of which have received funding from the U.S. One drug developed by the U.S. Army has shown promising results when tested in monkeys. "We think this may work because of the animal models but until you do the studies in humans, you just don't know," said Fred Hayden, an infectious diseases specialist at the University of Virginia, who was not involved in the research. While animal studies for vaccine candidates have been encouraging, it's unclear what dose humans would need. A Canadian company, Tekmira, has a $140 million contract with the U.S. government to develop a Ebola vaccine. An early test of the shot in healthy humans was stopped recently after the Food and Drug Administration asked for more safety information.
SHOULD EXPERIMENTAL DRUGS BE USED NOW?
Scientists are split on whether or not it is a good idea to try experimental drugs and vaccines before they are approved but the prospect is being informally discussed.
"Given the prolonged and unprecedented nature of the epidemic, we need to carefully consider this," said Dr. Peter Piot, the co-discoverer of Ebola in 1976 and director of the London School of Hygiene and Tropical Medicine.
The World Health Organization has no plans to facilitate any clinical trials during this outbreak, spokesman Gregory Hartl said. Other experts say it's unethical to use treatments or vaccines that haven't been properly tested, and warn the results could be disastrous.
"None of these drugs or vaccines are ready to be used in humans from a legal point of view," said Dr. Heinz Feldmann, chief of virology at the U.S. National Institute of Allergy and Infectious Diseases.
It would be impossible to vaccinate or treat everyone in the region but if any tests do proceed, they would probably be focused on those at highest risk: health care workers.
The American woman who got the experimental drug in Liberia worked at a hospital where Ebola patients were treated. It's not known what kind of treatment she received. If health care workers are treated, "We will have to explain why some people are getting the vaccine and others are not," Feldmann said, adding there are still vast areas of West African communities suspicious of Western aid workers and their treatments. "At the moment, it doesn't even look like the local population wants it."
http://english.ahram.org.eg/News/107616.aspx


Clic here to read the story from its source.